The dangerous Hepatitis C virus affects as many as 150 million people globally and possibly 12 million in India.
A latest breakthrough treatment for the dangerous Hepatitis C virus could soon be available in India as 11 Indian firms have been given permits by its American manufacturer following an acceptance from US authorities.
The medication known as Epclusa which is made to cure all genotypes of the Hepatitis C virus by Gilead Sciences in its newest breakthrough treatment was a week ago authorized by the US Food and Drug Administration (FDA).
This pan-genotypic treatment does not have gene-type examining, eliminate the need for expensive gene–type diagnostics, enabling physicians and specialists to prescribe the medication to anyone who tests positive for Hepatitis C, by taking one tablet a day for 8-12 weeks they are cured.
“The acceptance of Epclusa represents an important advancement in the international attempt to control and possibly remove HCV as it provides a safe, simple and effective treatment for almost all HCV-infected patients, regardless of genotype,” said Ira Jacobson, MD, chairman of the Division of Medicine at Mount Sinai Beth Israel, New York and a principal investigator in the Epclusa clinical trials.
“Building on the established backbone of sofosbuvir, Epclusa demonstrated continually high treat prices across all genotypes, such as among patients with genotype 2 and 3, who typically have needed ribavirin or other multi-pill regimens,” he said.
As part of its effort to make it a cost-effective treatment, Gilead Sciences, together with its 11 associates in India, are revolutionary a Voluntary Licensing model that transfers technology and Intellectual Property for newest therapies and treating for viral Hepatitis and HIV.
Gilead, in 2014, licensed its newly-approved HCV routines to 11 of India’s drug organizations, such as the prospective Epclusa, which had not yet been cleared by the US FDA.
“This forward thinking strategy started out for these Indian companies the industry across all of India for generic versions of these drugs, plus the marketplace 100 other countries,” an industry source said.
Because of India’s abilities in general production, where high quality and low cost co-exist side available, Gilead Sciences recognized that to increase individual accessibility and to set up these life-saving treatments to low earnings nations around the entire world to the patients who need therapy most.
“It would be mutually valuable to license the Intellectual Property for its new HCV medications to companies in India which had already recognized supply sequence linkages with nations across Africa, Asia, Eastern Europe, Mongolia, and other hard to get marketplaces”, industry sources said.